Loading patent…
AssigneesFuwai Central China Cardiovascular Hospital, Central China Subcenter of National Center for Cardiovascular Diseases
InventorsYong ZHAO, Zhaoyun CHENG, Fangyan LIU, Yinghui GE, Qing LIN, Yakun NIU, Qingdan YANG, Xinlei QI
Estimating the term…
A molecular marker for diagnosing, prognosis, evaluating, and treating cardiac fibrosis and belongs to the technical field of biomedicine. The present disclosure provides a molecular marker capable of diagnosing cardiac fibrosis, assessing the severity of cardiac fibrosis, evaluating the prognosis of cardiovascular disease with cardiac fibrosis, or evaluating the prognosis of acute myocardial infarction. The molecular marker comprises hepatocyte growth factor. It has been found that HGF is significantly elevated in the plasma of patients with cardiac fibrosis and also considerably elevated in patients with aortic stenosis before surgery. Therefore, HGF can be used to diagnose cardiac fibrosis and evaluate its severity.
A molecular marker, wherein the molecular marker comprises hepatocyte growth factor and the molecular marker has any one of the following functions:
A method for preventing or treating cardiac fibrosis, comprising administering any one or a combination of hepatocyte growth factor, hepatocyte growth factor signal pathway blocker, and neutrophil infiltration inhibitor to a subject in need.
A drug wherein the drug has any one of the following functions:
A method for diagnosing and/or evaluating cardiac fibrosis, the method comprises:
A method for evaluating the prognosis of acute myocardial infarction, the method comprises:
A method for improving the prognosis of a subject experiencing acute myocardial infarction, the method comprises:
Dependencies are inferred from the claim text.